Do beta‑lactam antibiotics and merrem (sarilumab) cause neutropenia?

Beta-Lactams and Meropenem Can Cause Neutropenia

Yes, beta-lactam antibiotics including meropenem (Merrem) can cause neutropenia, typically occurring after ≥10 days of high-dose intravenous therapy with an incidence of approximately 10%, though this adverse effect is generally reversible within 1-7 days after discontinuation.

Mechanism and Incidence

Beta-lactam-induced neutropenia is a well-documented adverse reaction that occurs through both direct toxic effects on granulopoiesis and immune-mediated mechanisms 1, 2. The key risk factors include:

• Duration of therapy: Incidence rises dramatically from <0.1% with short courses to 5-15% with treatment ≥10 days 2
• Cumulative dose: Higher total antibiotic exposure increases risk 3
• Specific agents: All beta-lactams can cause this, including carbapenems like meropenem 4, 5

The FDA label for Merrem specifically lists neutropenia as a post-marketing adverse reaction, though the exact incidence is not quantified 6. In critically ill patients receiving high-dose meropenem (3-6 g/day), neutropenia occurred in 4.5% versus 3.6% with standard dosing, showing no significant difference 5.

Clinical Presentation and Monitoring

Warning signs that may precede neutropenia include:

• Fever (often appears before neutropenia develops)
• Rash (another alarm sign) 3

Bone marrow findings characteristically show numerous immature granulocyte precursors but lack of well-differentiated myeloid elements 2.

Management Algorithm

1. Immediate discontinuation of the offending beta-lactam is the cornerstone of treatment 4, 1

2. Recovery timeline: Unlike other drug-induced neutropenias, beta-lactam-induced neutropenia typically resolves within 1-7 days (>95% of cases) after stopping the drug 2

3. Supportive care:

   • If patient becomes febrile and septic, initiate neutropenic sepsis treatment immediately 4
   • Consider G-CSF (granulocyte colony-stimulating factor) to accelerate recovery, with daily neutrophil monitoring 4

4. Mortality risk: Remains low at 2.5-5% 4

Critical Decision: Switching to Alternative Beta-Lactams

When beta-lactam therapy remains necessary, you can safely switch to a beta-lactam from a different structural class (different R1 side chain), particularly from a separate antibiotic family 1.

Specific guidance:

• Penam drugs (penicillins like piperacillin) do NOT strongly cross-react with cephem drugs (cephalosporins) and vice versa 7
• Carbapenems like meropenem have distinct structures from both groups
• Future use of beta-lactams with differing R1 side chains should not be contraindicated following beta-lactam-induced neutropenia 1
• Close laboratory monitoring (serial CBCs) is mandatory when rechallenge is attempted 1

Important Caveats

The apparent contradiction between clinical trial data (which rarely report neutropenia) and real-world experience exists because most trials involve treatment courses <2 weeks, missing the critical risk period 3. This is why post-marketing surveillance has been essential in recognizing this complication.

In patients with renal impairment, the FDA specifically warns that thrombocytopenia (not just neutropenia) has been observed with meropenem, and the incidence of various adverse events including seizures increases in those with creatinine clearance 10-26 mL/min 6.

Context for neutropenic patients: Ironically, the IDSA guidelines recommend meropenem as first-line empirical therapy FOR febrile neutropenia in high-risk cancer patients, as monotherapy with anti-pseudomonal beta-lactams (including meropenem) is highly effective for treating infections in this population 8. The neutropenia being treated in these guidelines is from chemotherapy, not from the antibiotics themselves.